

Bibliografía

- Abdou H.M. (1989). "Dissolution, Bioavailability and Bioequivalence" Ed. Easton, Pennsylvania, Mack Publishing Co.
- Adeyeye, M.C.; Brittain, H.G. (Eds.). (2008). *Preformulation in solid dosage form development*. Marcel Dekker, New York.
- Agrawal, A.M., Neau, S.H., Bonate, P.L. (2003). "Wet Granulation Fine Particle Ethylcellulose Tablets: Effect of Production Variables And Mathematical Modeling of Drug Release". *AAPS Pharm Sci.* 5 (2), Article 13.
- Aiache, J.M.; Besner, J.G.; Buri, P.; Leblanc, P.P.; Lesne, M. (1985). *Traité de Biopharmacie et Pharmacocinétique*, deuxième édition. Ed. Vigot. Paris.
- Akaike, H. (1976). "An Information Criterion (AIC)". *Mathematics Science*, 14: 5-9
- Alderman D.A. (1984) "Review of cellulose in hydrophilic matrices for oral controlled-release dosage forms". *Int. J. Pharm. Technol. Prod. Mfr.* 5, 1-9.
- Amidon, G. L. y Bermejo, M. (2005). *Modern Biopharmaceutics V. 6.0*. J. Price, Tsrl, inc.
- Amidon, G. L., Lennernas, H., Shah, V. P., y col. (1995). "A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability". *Pharm Res* 12(3): 413-20.
- Ando, H.Y.; Radebaugh, G.W. (2003) "Preformulación". En: Gennaro AR (Ed.); *Remington Farmacia*, 20ª Ed. Editorial Panamericana, Buenos Aires.
- Andretta HA. (2003). Fármacos de acción prolongada. Mecanismos de liberación. Usos de distintos modelos. *Lat. Am. J. Pharm.*, 22(4), 355-364
- Banakar U.V (1992). *Pharmaceutical Dissolution Testing*. Ed. Marcel Dekker; New York
- Banker, G.; Rhodes, C.T. (1996) *Modern Pharmaceutics*, third edition. Ed. Marcel Dekker, Inc. New York.
- Bauer L. A. (2001). *Applied clinical pharmacokinetics*. McGraw-Hill. New York.
- Baveja S.K., Ranga Rao K.V. (1986). "Sustained release tablet formulation of centperazine", *Int. J. Pharm.*, 31, 169-174.
- Baveja, S.K., Ranga Rao, K.V., Padmalatha, Devi K. (1987). "Zero-order release hydrophilic matrix tablets of β -adrenergic blockers" *Int. J. Pharm.*, 39, 39-45.
- Beal, S. L. 1987. Some clarifications regarding moments of residence times with pharmacokinetic models. *Journal of Pharmacokinetics and Biopharmaceutics*, Vol. 15: 75 - 92.
- Benet, L. Z., Amidon, G. L., Barends, D. M., y col. (2008). "The use of BDDCS in classifying the permeability of marketed drugs". *Pharm Res* 25(3): 483-8.
- Benet, L.Z. Massoud, N., Gambertoglio, J.G., eds, (1984): *Pharmacokinetic Basis for Drug Treatment*. Raven Press. New York.
- Bertran, M., Mosekilde, E., Westerhoff, H.V., (2008). "Biosimulation in Drug Development", en *Correlation between in vitro in situ and in vivo models*, pgs 89-113. Wiley-VCH Verlag GmbH & Co. KgaA. Weinheim.
- Bettini, R., Catellani, P.L., Santi, P., y col. (2001). "Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate". *J. Control. Rel.* 70, 383-391.
- Birkett, Donald J. (2005) *Farmacocinética Fácil*. McGraw-Hill Interamericana de España. Madrid.
- Blume, H. H. y Schug, B. S. (1999). "The biopharmaceutics classification system (BCS): class III drugs-better candidates for BA/BE waiver?" *Eur J Pharm Sci* 9(2): 117-21.
- Bolton S. 2010. *Pharmaceutical Statistics*, Marcel Dekker, 4th Edition, New York.
- Bonate, P.L (2006). *Pharmacokinetic-pharmacodynamic: modelling and simulation*. Springer. New York.

Boroujerdi, M. (2002). "Multiple dosing kinetics: one-compartment model" en *Pharmacokinetics. Principles and Applications*. McGraw-Hill. New York.

Bourne, D.W.A. y col. (1986). *Pharmacokinetics for the Non-mathematical*. MTP Press Limited. Lancaster.

Brandon, E.F.A., Raap, C.D., Meijerman, I. y col. (2003). An update on *in vitro* test methods in human hepatic drug biotransformation research: pros and cons. *www. Sciencedirect.com*. Available online 9 May 2003.

Brockmeier, D, von Hattinberg, H M. (1982). "In vitro-in vivo correlation, a time scaling problem?. Basic considerations on in vitro dissolution testing". *Arzneim. Forsch*, 32(3): 248-251

Brockmeier, D. (1986). In vitro/in vivo correlation of dissolution using moments of dissolution and transit times. *Acta Pharm. Techn.* 32, 164-174.

Burton, M.E., Shaw, L.M., Schentag, J.J., Evans, W.E. (2006) *Applied Pharmacokinetics and Pharmacodynamics. Principles of therapeutic drug monitoring*. 4ª Ed. Lippincott Williams and Wilkins. Philadelphia.

Bulgarelli E., Forni F., Bernabei M.T. (2000). Can kinetic analysis be a tool for evaluating pore characteristics? *Journal of Encapsulation* 6(13): 701-710.

Carlson, T.J.; Fisher, M.B. (2008). "Recent advances in high throughput screening for ADMET properties". *Comb. Chem. High T. Scr.* 11: 258-264.

Cascales Angosto, M., Gómez-Lechón, M.J. (2004). *Citocromo P-450*. Instituto de España. Real Academia de Farmacia. Eds. Madrid.

Castellani, P., Vaona, G., Plazzi, P., y col. (1988). "Compressed matrices: formulation and drug release kinetics". *Acta Pharm. Technol.*, 34, 38-41.

Chen, M.L. (1992) An alternative approach for assessment of rate of absorption in bioequivalence studies. *Pharma. Res.* 9: 1380-1385.

Cheng, H. y Jusko, W. J. (1993). Mean residence time of oral drugs undergoing first-pass and linear reversible metabolism. *Pharmaceutical Research*, Vol. 10: 8-13.

Chien, Y. W. (1983). "Potential developments and new approaches in oral controlled-release drug delivery systems". *Drug Dev. Ind. Pharm.* 9, 1291-1330.

Chien, Y. W. (1992). *Novel Drug Delivery Systems*. Marcel Dekker Inc. NY.

Chow, S.C., Liu, J.P. (2000). *Design and Analysis of Bioavailability and Bioequivalence Studies*. Markel Dekker, Inc., New York, NY.

Chow, S.C., Wang, H. (2001). On sample size calculations in bioequivalence trials. *J Pharmacokinet. Pharmacodyn*, 28(2): 155-169.

Cochran, W.G., Cox, G.M. (1985). *Diseños experimentales*. Ed. Trillas. 9ª edición. Méjico.

Colburn, W.A. (1983). A time-dependent volume of distribution term used to describe linear concentration-time profiles. *J. Pharmacokin. Biopharm.* 11: 389.

Costa, P., Sousa Lobo, J.M. (2001). "Modeling and comparison of dissolution profiles". *Eur. J. Pharm. Sci.*, 13, 123-133.

CPMP/ EWP/QWP/1401/98 Rev. 1/ Corr. The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit. Committee for medicinal products for human use (CHMP). 2010. Guideline on the investigation of bioequivalence.

CPMP/EWP/280/96. The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit. Committee for proprietary medicinal products (CPMP). 1999. Note for guidance on modified release oral and transdermal dosage forms: section II (pharmacokinetic and clinic evaluation).

Crommelin, D.J.A.; Sindelar, D.S. (Eds.). (2002) *Pharmaceutical Biotechnology* 2ª Ed. Taylor & Francis, Philadelphia.

Curry, S.H. (1977). *Drug Disposition and Pharmacokinetics*, second edition. Ed. Blackwell Sciebtific Publications. Oxford.

DiPiro, J.T., Blovin, R.A., Pruemmer, J.M. (1996). *Concepts in Clinical Pharmacokinetics: A Self-Instructional Course*. American Society of Health-System. Bethesda.

DiStefano III, J. J. y Landaw, E. M. (1984). Multiexponential, multicompartmental, and noncompartmental modeling. I. Methodological limitations and physiological interpretations., *American Journal of Physiology*, Vol. 246: R651 - R664.

Doherty, M.M., Charman, W.N. (2002). The mucosa of the small intestine. How clinically relevant as an organ of drug metabolism? *Clin Pharmacokinet*; 41: 235-53.

Doménech, J.; Martínez, J.; Plá Delfina, J.M. (1997) *Biofarmacia y Farmacocinética*. Vol. I. Ed. Síntesis. Madrid.

Dürig, T., Fassihi, R. (2002). “Guar-based monolithic matrix systems: effect of ionizable and non-ionizable substances and excipients on gel dynamics and release kinetics”. *J. Control. Rel.* 80, 45-56.

Edginton, A.N., Schmitt, S. y Willmann, S. (2006). “Development and Evaluation of a Generic Physiologically Based pharmacokinetic model for children”. *Clin. Pharmacokin* 45 (10): 1013-1034.

El-Arini, S.K., Leuenberger, H. (1998) “Dissolution properties of praziquantel-PVP systems”. *Pharm. Acta Helv.* 73, 89-94.

EMA/CHMP/EWP/192217/2009. The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit. Committee for medicinal products for human use (CHMP). 2010. Guideline on validation on bioanalytical methods.

Emslie-Smith, D. Paterson, C.R., Scratcherd T, *et al.* (1988) *Textbook of Physiology*. 11^a ed. Churchill Livingstone. Edimburg.

Endreny, L., Fritsch, S., Yan, W. (1991). C_{max}/AUC is a clearer measure than C_{max} for absorption rates in investigations of bioequivalence. *Int. J. Clin. Pharmacol. Ther. Toxicol.* 29: 394-399.

European Pharmacopoeia 6.0, vol. 1. (2007). “Guidance on dissolution testing”. 273.

FDA (2000a). FDA guidance for industry. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. .

FDA (2000b). Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System.

Ferrero, C., Muñoz-Ruiz, A., Jiménez-Castellanos, M.R. (2000). “Fronts movement as a useful tool for hydrophilic matrix release mechanism elucidation”. *Int. J. Pharm.*, 202, 21-28.

Fisher, M.B., Paine, M.F., Strelevitz, T.J., Wrighton, S.A. (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in drug metabolism. *Drug Metab Rev*; 33: 273-97.

Flockhart, D.A. (2007). Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. <http://medicine.iupui.edu/flockhart/table.htm>. Accessed [September 2008].

Ford, J. (1987). “Importance of drug type, tablet shape and added diluents on drug release kinetics from hydroxypropylmethylcellulose matrix tablets”. *Int. J. Pharm.* 40, 223-234.

Ford J. (1991) “Mathematical modelling of drug release from hydroxypropylmethylcellulose matrices”. *Int. J. Pharm.*, 71, 95-104.

Furra, A. (2006). Role of pharmacologically active metabolites in drug discovery and development. *Drug discovery today*; 11:133-42

Gabrielson, J. y Weiner, D.: *Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Applications*, 3rd edition, Swedish Pharmaceutical Press. Sweden. 2000.

Gardiner, S.J., Begg, E.J. (2006). Pharmacogenetics, drug-metabolizing enzymes and clinical practice. *Pharmacol Rew*, 58: 521-90.

Gibaldi, M. (1991). *Biopharmaceutics and Clinical Pharmacokinetics*, 4^a ed. Lea & Febiger. Malvern.

Gibaldi, M. (2005) *Biopharmaceutics and Clinical Pharmacokinetics* 4TM Ed. Lea and Febiger. Philadelphia.

Gibaldi, M.; Perrier, D. (1982) *Farmacocinética*. Ed. Reverté, S.A. Barcelona.

Gibson, M. (Ed.) (2004). *Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form*. CRC Press LLC, Boca Raton, Florida.

Gibson, Mark (2004). *Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form*. Interpharm CRC Press, Boca Ratón, Florida, NY.

Graebner, R.W. (2002). Study Design with SAS: Estimating Power with Monte Carlo Methods. *SUGI 27. Proceedings*, Paper 265-25.

Graebner, R.W. (2002). Study Design with SAS: Estimating Power with Monte Carlo Methods. *SUGI 27. Proceedings*, Paper 265-25.

Grandison, M.K. y Boudinot, F.D. (2000). "Age-Related Changes in Protein Binding of Drugs. Implications for Therapy". *Clin. Pharmacokinet*, 38(3) 271-290.

Greenblatt, D.J. y Shader, R.I. (1985): *Pharmacokinetics in Clinical Practice*. Saunders Co. Philadelphia,.

Guidance for Industry. (1997). *Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In vitro/In vivo correlations* CDER, September.

Harland R.S., Gazzaniga A., Sangalli M.E., y col. (1988) "Drug/polymer matrix swelling and dissolution", *Pharm. Res.*, 5, 488-494.

Hauck, K.W., Anderson S. (1984). A new statistical procedure for testing equivalence in two groups comparative bioavailability trials. *J Pharmacokinet Biopharm*, 12: 83-91 .

Hauck, W.W., Foster T., Sheinin E., y col. (2005) "Oral dosage forms performance test: new dissolution approaches". *Pharm. Res.*, 22, 2, 182-187.

Hausche, D., Steinijs, V.W., Diletti, E. (1990). A distribution-free procedure for the statistical analysis of bioequivalence studies. *Int J Clin Pharm Ther and Toxicol*, 28: 72-78.

Hauschke, D., Steinijs, V.W., Diletti, E. (1992). Sample size determination for bioequivalence assessment using a multiplicative model. *J Pharmacokinet Pharmacodyn* 20: 557-561.

Hedaya Moshen, A. (2007). *Basic pharmacokinetics*. CRC Press. Boca Ratón.

Higuchi T. (1961). "Rate of release of medicaments from ointment bases containing drugs in suspensions. *J. Pharm. Sci.*, 52, 1145-1149.

Hillery, A.M., Lloyd, A.W, Swarbrick, J. (2001). *Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists*. Taylor and Francis, NY.

Hixson, A W. Crowell, J H. (1931)."Dependence of reaction velocity upon surface and agitation. I: Theoretical consideration". *Ind Eng Chem*. 923-931

Ho, R.J.Y.; Gibaldi, M. (2003) *Biotechnology and Biopharmaceuticals. Transforming proteins and genes into drugs*. John Wiley & Sons, Hoboken.

Holleberg, P.F. (2002) Characteristics and common properties of inhibitors, inducers and activators of Cyp enzymes. *Drug metabolism Reviews*, 34:17-35.

Hopfenberg H.B.)1976) In: Paul D.R.; Harris F.W. (Eds.) "Controlled Release Polymeric Formulations. ACS Symposium Series 33 American Chemical Society, Washington D.C.; 26-31.

Horkovics-Kovats, S. y Zlatos, P. (2006). Asymptotics and bioavailability in a 17-compartment pharmacokinetic model with enterohepatic circulation and remetabolization. *Mathematical Biosciences*, Vol. 203: 19 - 36.

Houin, G. (1990): *Pharmacocinétique*. Ellipses. París,

Huser, J. (Ed.) (2006). *High throughput-screening in drug discovery*. Wiley-VCH, Weinheim, Alemania.

Ingelman-Slundberg, M. (2005). Genetic polymorphisms of cytochrome P450 2D6: clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenom J*, 5:6-13.

Izquierdo, M., Lanao, J.M., Cervero, L. y col. (1992) Population Pharmacokinetics of Gentamicin in Premature Infants. *Ther. Drug Monit*. 14: 177.

Kasim, N. A., Whitehouse, M., Ramachandran, C., y col. (2004). "Molecular properties of WHO essential drugs and provisional biopharmaceutical classification". *Mol Pharm* 1(1): 85-96.

Katzhendler I., Hoffman A., Goldberger A., y col. (1997) "Modelling of drug release from erodible tablets". *J. Pharm. Sci.* 86; 110-115.

- Khan, G.M. (2001). "Controlled Release Oral Dosage Forms: Some Recent Advances in Matrix Type Drug Delivery Systems", *The Sci.* 1 (5), 350-354
- Khan, K.A. (1975). The concept of dissolution efficiency. *J. Pharm. Pharmacol.* 27, 48-49.
- Khan, K. Rhodes, C T. (1972). "Effect of compaction pressure on the dissolution efficiency of some direct compression systems". *Pharm Acta Helv.* 47: 594-607
- Kiang, T.K., Ensom, M.H., Chang, T.K. (2005). UDP-glucuronosyltransferases and clinical drug interactions. *Pharmacol Ther.* 106:97-132
- Kim, H., Fassihi, R. (1997). "Application of binary polymer system in drug release rate modulation, 2. Influence of formulation variables and hydrodynamic conditions on release kinetics". *J. Pharm. Sci.*, 86, 323-328.
- Kiriyama, A., Honbo, A. y Iga, K. (2008). Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans., *International Journal of Pharmaceutics*, Vol. 349: 53 - 60.
- Klein, T.E., Chang, M.K., Cho, K.L. *et al.* (2001). Integrating genotype and phenotype information: an overview of the PharmGKB project. *The Pharmacogenomics Journal*: 167-70.
- Korsmeyer, R.W., Gurny R, Doelker E, y col. (1983) "Mechanisms of solute release from porous hydrophilic polymers". *Int J Pharm.*, 15, 25-35.
- Labaune, J.P. (1987) *Pharmacocinétique*, 2e édition. Ed. Masson. Paris.
- Labaune, J.P. (1988). *Pharmacocinétique, Principes fondamentaux*. 2^a Edition. Masson. Paris.
- Lacey L.F., Bye A., Kneene O.N. (1995) Glaxo's experience of different absorption rate metrics of immediate release and extended release dosage forms. BIO-international Conference, Rockville MD USA (19-9-1994), vol29, n°3, 821-840.
- Landaw, E. M. y DiStefano III, J. J. (1984). Multiexponential, multicompartmental, and noncompartmental modeling, II. Data analysis and statistical considerations. *American Journal of Physiology*, Vol. 246: R665 - R677.
- Langenbucher, F. 1972. "Linearization of dissolution rate curves by Weibull distribution". *J Pharm Pharmacol.* 24: 979-981.
- Le Blanc, Pierre-Paul. (1990), en "Traité de Biopharmacie et Pharmacocinétique, Editions Vigot, deuxième Edition, Montreal.
- Lee, P. I. D. y Amidon, G. L. 1996. *Pharmacokinetic analysis. A practical approach*. Lancaster: Technomic Pub. Co. Inc.
- Lennernas, H. y Abrahamsson, B. (2005). "The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension". *J Pharm Pharmacol* 57(3): 273-85.
- Lennernas, H., Ahrenstedt, O., Hallgren, R., y col. (1992). "Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man". *Pharm Res* 9(10): 1243-51.
- Lindenberg, M., Kopp, S. y Dressman, J. B. (2004). "Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system". *Eur J Pharm Biopharm* 58(2): 265-78.
- Llabot, J.M., Manzo, R.H., Allemandi, D.A. (2004). "Drug release from carbomer: carbomer sodium salt matrices with potential use as mucoadhesive drug delivery system". *Int. J. Pharm.*, 276, 59-66.
- Lobenberg, R. y Amidon, G. L. (2000). "Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards". *Eur J Pharm Biopharm* 50(1): 3-12.
- Loo, J. C. K.; Riegelman, S. (1968). New Method for Calculating the Intrinsic Absorption Rate of Drugs. *Pharm. Sci.* 57: 918-928.
- Maples, H.D. James, L.P., Stowe, C.D. (2006) "Special pharmacokinetic and pharmacodynamics considerations in children". En: *Applied Pharmacokinetics and Pharmacodynamics. Principles of therapeutic drug monitoring*. 4^a Ed. Lippincott Williams and Wilkins. Philadelphia.
- Matzke, G.R., Comstock T.J. (2006) "Influence of Renal Function and Dialysis on Drug Disposition". En: *Applied Pharmacokinetics and Pharmacodynamics. Principles of therapeutic drug monitoring*. 4^a Ed. Lippincott Williams and Wilkins. Philadelphia.

- Mayersohn, M.B. (1992) "Special pharmacokinetic considerations in the elderly". En: *Applied Pharmacokinetics*. 3ª Ed. Applied Therapeutic Inc. Vancouver.
- Meineke I. (1987). A simple BASIC program for the calculation of nonparametric confidence intervals in bioequivalence testing. *Comput Methods Programs Biomed*, 24: 65-71.
- Moore, J. W. Flanner, H. H. (1996). "Mathematical comparison of dissolution profiles". *Pharm Tech* 64-74
- Munday, D.L., Cox P.H. (2000). "Compressed xanthan and karaya gum matrices: hydration, erosion and drug release mechanisms". *Int. J. Pharm.*, 203, 179-192.
- Niazi, S. 1979: *Textbook of Biopharmaceutics and Clinical Pharmacokinetics*. Appleton-Century-Crofts. New York.
- Niles, A.L.; Moravec, R.A.; Riss, T.L. (2008). "Update on in vitro cytotoxicity assays for drug development". *Expert Opin. Drug Discov.* 3: 655-669.
- Notari, R.E (1987). *Biopharmaceutics and Clinical Pharmacokinetics*. Marcel Dekker, Inc. New York.
- Noyes, A S, Whitney, W R. (1997). "The rate of solution of solid substances in their own solutions". *J Am Chem Soc*, 19: 930-934.
- Oh, D. M., Curl, R. L. y Amidon, G. L. (1993). "Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model". *Pharm Res* 10(2): 264-70.
- Ohno, Y., Hisaka, A., Ueno, M., Suzuki, H. (2008). General framework for the prediction of oral drug interactions caused by CYP3A4 induction from *in vivo* information. *Clin Pharmacokinet*, 47:669-80.
- Okusanya, O., et. al. (2007). Compartmental pharmacokinetic analysis of amprenavir with secondary peaks., *Antimicrobial Agents and Chemotherapy*, Vol. 51: 1822-1826.
- Peppas N.A., Ritger P.L. (1987). "A Simple Equation for Description of Solute Release I. Fickian and Non-Fickian Release Form Non-swellable Devices in the Form Slabs, Spheres, Cylindres or Disc". *J. Control. Rel.*, 5, 23-36.
- Peppas, N.A., Sahlin, J.J. (1989). "A simple equation for the description of solute release, III. Coupling of diffusion and relaxation". *Int. J. Pharm.* 57, 169-172.
- Pillay V., Reza F. (1999). "In vitro release modulation from crosslinked pellets to the gastrointestinal tract". *J. Control. Rel.* 59; 229-242.
- Plá Delfina, J.M. (1974). *Manual de Iniciación a la Biofarmacia*. Romargraf, S.A. Barcelona.
- Pollack, G.M., Brouwer, L.R. (1991) Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of Valproic acid in rat. *Journal of Pharmacokinetics and Biopharmaceutics*, 19: 189-225.
- Polli, J. E., Yu, L. X., Cook, J. A., y col. (2004). "Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities". *J Pharm Sci* 93(6): 1375-81.
- Potvin, D., DiLiberti, C.E., Hauck, W.W., Parr, A.F., Schuirmann, D.J. y Smith, R.A. (2007). Sequential design approaches for bioequivalence studies with crossover designs. *Pharmaceutical Statistics*,7: 245-262.
- Rang HP (Ed.) (2006) Drug Discovery and Development. Technology in Transition. Churchill Livingstone Elsevier, Edinburgh.
- Rathbone, M.J., Hadgraft, J., Roberts, M.S. et al. (2008). Modified-Release Drug Delivery Technology (vol 1), 2nd Ed. Informa Healthcare, NY.
- Rescigno, A. (2004). On the use of pharmacokinetic models. *Physics in Medicine and Biology*, Vol. 49: 4657-4676.
- Reza, S., Quadir, M.A. (2003). "Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery". *J. Pharm. Pharm. Sci.*, 6, 274-291.
- Rinaki, E., Dokoumetzidis, A., Valsami, G., y col. (2004). "Identification of biowaivers among Class II drugs: theoretical justification and practical examples". *Pharm Res* 21(9): 1567-72.
- Ritschel, W.A.; Kearns G.L. (1998) Handbook of Basic Pharmacokinetics, 5th Edition, Ed. American Pharmaceutical Association. Washington, D.C.

- Ristchel, W.A, Kearns, G.L. (2004). Handbook of Basic Pharmacokinetics-including clinical applications. 6th Washington D.C.. APhA.
- Ritschel, W.A. y Kearns, G.L. (2009). "Pharmacokinetics of Multiple Dosing" en *Handbook of basic pharmacokinetics-Including clinical applications*. 7ª ed. American Pharmacists Association. Washington.
- Rivory L.P. (1992). Axial tissue diffusion can account for the disparity between current models of hepatic elimination for lipophilic drugs. *Journal of Pharmacokinetics and Pharmacodynamics* 20: 19-61.
- Robinson, J.R., Lee, V. H. L. 1987 *Controlled Drug Delivery*. Marcel Dekker Inc. NY.
- Rodda BE, Davis RL. 1980. Determining probability of an important difference in bioavailability. *Clin Pharmacol Ther*, 28: 247-252.
- Rodgers, T. y Rowland M. (2000). Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes. *Pharmaceutical Research*, 24:918-933.
- Rowland, M. y Tozer, T.N. (2011) *Clinical Pharmacokinetics and pharmacodynamics: Concepts and Applications*. 4rd Ed. Lippincott Williams and Wilkins. Philadelphia.
- Rowland, M. (1972). Influence of route of administration on drug bioavailability. *Journal of Pharmaceutical Sciences*, Vol. 61:70 - 74.
- Rowland, M. y Tozer, T.N. (1995). Clinical Pharmacokinetics. Concepts and Applications. 3ª ed. Lea and Febiger. London
- Rowland, M., Tozer, T.N. (1989). Clinical Pharmacokinetics. Concepts and Applications. Lea and Febiger. Philadelphia.
- Rowland, M., Tozer, T.N. (2010). Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4rd Edition. Lippincott Williams and Wilkins. Philadelphia.
- Roy, S.D., Hawes, E.M., Midha K.K. (1987) Influence of Urinary pH on the Disposition of Methoxyphenamine and Three Metabolites in Humans. *J. Pharm. Sci.* 76(6): 427-432.
- Sahajwalla, C.G. (2004). New Drug Development. Regulatory Paradigms for Clinical Pharmacology and Biopharmaceutics. Marcel Dekker Inc. NY.
- Schuirman DJ. 1987. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. *J Pharmacokinetic Biopharm*, 15: 105-110.
- Segre, G. (1982). Pharmacokinetics - Compartmental representation, *Pharmacology and Therapeutics*, Vol. 17: 111 - 127.
- Shargel L., 2004: Applied biopharmaceutics & pharmacokinetics. Appleton & Lange Reviews/McGraw-Hill
- Shargel L., Yu A.B.C. (1993): *Applied Biopharmaceutics and Pharmacokinetics*. Appleton and Lange. Norwalk, Connecticut,
- Shargel, L. Wu-Pong, S., Yu, A.B.C. (2005) *Applied Biopharmaceutics and Pharmacokinetics*. 5ª Ed. McGraw-Hill Companies. Medical Pub. Division. New York.
- Shargel, L. y Yu, A.B.C. (1980). "One-compartment open model" En: SHARGEL, L. y YU, A.B.C.; *Applied Biopharmaceutics and Pharmacokinetics*. Appleton Century Crofts. New York.
- Shargel, L., Yu, A.B.C. (1985). Applied Biopharmaceutics and Pharmacokinetics. Appleton Century Crofts. Norwalk, Connecticut.
- Shargel, L., Yu, A.B.C. (1992) Applied Biopharmaceutics and Pharmacokinetics, third edition, Ed. Appleton and Lange. Norwalk, Connecticut.
- Sheppard, C. W. 1948. The theory of the study of transfers within a multi-compartement system using isotopic tracers. *Journal of Applied Physiology*, Vol. 19: 70.
- Shepard, A.T., Reuning, R.H y Aarons, L.J. (1985) Estimation of area under the curve of drugs subject to enterohepatic cycling. *Journal of Pharmacokinetics and Biopharmaceutics*, 13: 589-608.
- Siepmann J., Peppas N.A. 2001 "Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC)" *Adv. Drug Del. Rev.*, 48, 139-157.
- Steinijans, V.W., Diletti, E. (1983). Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. *Eur J Clin Pharmacol*, 24: 127-136.
- Study size ver 2.0. <http://WWW.CREOSTAT.COM>, StudySize@CreoStat.com

Supac-MR: Guidance for Industry. 1997 SUPAC-MR: Modified Release Solid Oral Dosage Forms FDA

Takada, K., Asada, S. (1981). A model independent approach to describe the blood disappearance profile of intravenously administered drugs. *Chem. Pharm. Bull* 29: 1462.

The United States Pharmacopeial, USP 32/NF 27, vol. 1. 2009. "Sección <1088> Evaluación in vivo e in vitro de formas farmacéuticas". Pg. 601-602

Theeuwes, F. (1983). "Osmotic system development". *Drug Dev. Ind. Pharm.* 9, 1331-1357.

Thummel, K.E., Kunze, K.L., Shen, D.D. (1997). Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. *Advanced Drug Delivery Rev*; 27: 99-127.

Tozer, T.N., Rowland, M. (2006). *Introduction to pharmacokinetics and pharmacodynamics: the quantitative basis of drug therapy*. Lippincott Williams & Wilkins. Philadelphia.

Tubic-Grozdanic, M., Bolger, M. B. y Langguth, P. (2008). "Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds". *Aaps J* 10(1): 213-26.

US FDA Guidance. (1992). Statistical procedures for bioequivalence studies using a standard two-treatment crossover design, statement under 21 CFR 10.90.

USP 32-NF27 (2008).

Valko, K.; Reynolds, D.P. (2005). "High-throughput physicochemical and *in vitro* ADMET screening. A role in pharmaceutical profiling". *Am. J. Drug Delivery*. 3: 83-100.

Veng-Pedersen, P. (1986). A simple method for obtaining the mean residence time of metabolites in the body, *Journal of Pharmaceutical Sciences*, Vol. 75: 818 - 819.

Venkatakrishnan K., Obach RS., Rostami-Hodjegan A. 2007 Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. *Xenobiotica*, 37:1225-56

Viswanathan CT, Bansal S ,Booth B et al.2007. Workshop/Conference Report — Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays. *The AAPS Journal* 9(1) Article 4 (<http://www.aapsj.org>).

Wagner, J.G (1983). *Farmacocinética Clínica*. Editorial Reverté, S.A. Barcelona.

Wagner, J.G. (1993) *Pharmacokinetics for the Pharmaceutical Scientist*. Technomic Publishing Co. Lancaster.

Weibull, W. (1951). "A statistical distribution of wide applicability". *J Appl Mech* 19: 293-297.

Welling P.G., Tse F.L.S. (1988). *Pharmacokinetics*. Ed. Marcel Dekker. New York.

Welling P.G., Tse F.L.S., Dighe S.V. (1991). *Pharmaceutical Bioequivalence*. Ed. Marcel Dekker. New York.

White RE. 2000. "High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery". *Annu. Rev. Pharmacol. Toxicol., pharmtox.* 40: 133-157.

WHO (2006a). Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability, *Technical Report Series, No 937, 40th Report, Annex 7* WHO. Geneva.

WHO (2006b). Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. . *Technical Report Series, No 937, 40th Report, Annex 8*. WHO. Geneva.

Wijnand, H.P. (1992). On the assessment on bioequivalence in a two-period cross-over design. *Comput Methods Programs Biomed*, 37: 151-157.

Wijnand, H.P. (1993). Bioequivalence revisited: non-parametric analysis of two-period cross-over studies. *Comput. Methods Programs Biomed*, 40: 249-259.

Wilkinson, G.R. (2005) .Drug metabolism and variability among patients in drug response. *N Engl J Med*, 352; 21: 2211-21

Wilkinson, G. R. y Shand, D. G. (1975). *A physiological approach to hepatic drug clearance.*, *Clinical Pharmacology and Therapeutics*, Vol. 18: 377 - 390.

Willians III R.O., Reynolds T.D., Cabelka T.D., y col. (2002). "Investigation of Excipient Type and Kevel on Drug Release from Controlled Release Tablets Containing HPMC". *Pharm. Dev. Tech.* 7 (2), 181-193.

- Winter, M.E. (1994). *Farmacocinética Clínica Básica*. Díaz de Santos, S.A. Madrid.
- Winter, M.E. (2004) *Basic Clinical Pharmacokinetics*, 4ª ed. Lippincott Williams & Wilkins. Baltimore.
- Wright, J.D.; Boudinot, F.D. y Ujhelyi, R. (1996) Measurement and analysis of unbound drug concentrations. *Clin. Pharmacokinet*, 30 (6): 445 - 462.
- Wu, C. Y. y Benet, L. Z. (2005). "Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system". *Pharm Res* 22(1): 11-23.
- Yamaoka, K., Nakagawa, T. Uno, T. (1978). "Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations". *J Pharmacokinetic Biopharm.* 6:165-175
- Yamaoka, K., Nakagawa, T. y Uno, T. 1978. *Statistical moments in pharmacokinetics.*, Journal of Pharmacokinetics and Biopharmaceutics, Vol. 6: 547 - 558.
- Yu, L. X., Amidon, G. L., Polli, J. E., y col. (2002). "Biopharmaceutics classification system: the scientific basis for biowaiver extensions". *Pharm Res* 19(7): 921-5.
- Yuksel N., Arzu E. (2000). "Comparison on in vitro dissolution by ANOVA based, model-dependent and independent, methods". *Int. J. Pharm.* 209, 57-67.
- Zarzuolo A., Lanao J.M., López F.G., Sánchez Navarro A. (2002). Influence of the infusion rate on disposition of netilmicin in the isolated rat perfused kidney. *European Journal of Pharmaceutical Sciences* 16: 133-141.
- Zaske, D.E. (1984) "Pharmacokinetics of aminoglycosydes". En *The aminoglycoside antibiotics: a guide to therapy*. CRC Press. Boca Ratón.